Exelixis (EXEL) Total Non-Current Liabilities (2010 - 2026)
Exelixis (EXEL) posted quarterly Total Non-Current Liabilities of $540.5 million for Q2 2026, down 7.8% year-over-year from $586.2 million in Q2 2025, and down 6.6% quarter-over-quarter from $578.7 million in Q1 2026.
Exelixis (EXEL) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Exelixis' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $540.5 million for Q2 2026.
- In Q2 2026, Total Non-Current Liabilities fell 7.8% year-over-year to $540.5 million; the TTM figure through Apr 2026 stood at $540.5 million (down 7.8% YoY), while the FY2026 annual figure was $578.7 million, down 2.68% from the prior year.
- Total Non-Current Liabilities for Q2 2026 stood at $540.5 million, down from $578.7 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $594.6 million in Q1 2025, with the low at $347.8 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $543.7 million (2024), against an average of $534.7 million.
- The sharpest annual moves came in 2023 and 2026: Total Non-Current Liabilities soared 49.78% in 2023, then declined 7.8% in 2026.
- Exelixis' Total Non-Current Liabilities stood at $514.5 million in 2022, then increased by 13.54% to $584.2 million in 2023, then increased by 0.78% to $588.8 million in 2024, then fell by 6.55% to $550.2 million in 2025, then fell by 1.77% to $540.5 million in 2026.
- Business Quant data shows EXEL's Total Non-Current Liabilities at $540.5 million in Q2 2026, $578.7 million in Q1 2026, and $550.2 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Exelixis | 12.75 Bn | 11.91 Bn | 608.03 Mn | 527.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | 527.86 Mn |
| Apr 3, 2026 | 540.52 Mn |
| Jan 2, 2026 | 578.68 Mn |
| Oct 3, 2025 | 550.24 Mn |
| Jul 4, 2025 | 515.95 Mn |
| Apr 4, 2025 | 586.23 Mn |
| Jan 3, 2025 | 594.59 Mn |
| Sep 27, 2024 | 588.79 Mn |
| Jun 28, 2024 | 543.72 Mn |
| Mar 29, 2024 | 574.48 Mn |
| Dec 29, 2023 | 584.22 Mn |
| Sep 29, 2023 | 567.67 Mn |
| Jun 30, 2023 | 541.04 Mn |
| Mar 31, 2023 | 520.84 Mn |
| Dec 30, 2022 | 514.53 Mn |
| Sep 30, 2022 | 468.06 Mn |
| Jul 1, 2022 | 472.75 Mn |
| Apr 1, 2022 | 347.75 Mn |
| Dec 31, 2021 | 397.60 Mn |
| Oct 1, 2021 | 331.20 Mn |